Home page of the research group of Hassan Z. Khiabani Clinical Research group

Research areas
The safe and cost-effective management of patients with cardiovascular, inflammatory, immunological, and renal disorders is highly relevant and a common goal for specialists in clinical pharmacology, cardiology, nephrology and transplant medicine as well as for researchers of inflammatory and infectious diseases. The optimal treatment of most of these conditions requires an advanced diagnostic approach and involves a combination of many different drugs. The Clinical Trial Unit (CTU) at the Department of Pharmacology can offer round-the-clock monitoring of trial participants with overnight stays at the unit. This makes the unit particularly well-suited to trials that need extensive monitoring and frequent pharmacokinetic and pharmacodynamic testing. The observation room is equipped as an intensive care unit. The departments of Cardiology and Nephrology at Oslo University Hospital-Rikshospitalet have a long record of research improving diagnostics and treatment of cardiovascular and renal diseases and to increase knowledge about myocardial and renal function. The research profile of the Research Institute of Internal Medicine is to combine clinical medicine and molecular biology to establish a bridge between laboratory workbench and bedside medicine, thus making it possible to benefit from recent developments in immunology, biochemistry and molecular biology for use in clinical medicine. The strategy for the research group is to design, conduct/facilitate, analyze and report state-of-the-art multidisciplinary clinical studies at Oslo University Hospital (OUH) that fit with the research strategies of OUH and University of Oslo.

Current projects

  • Metadone use and abuse, a forensic perspective and clinical perspective
  • Sleep apnea syndrome in patients with heart failure and paroxysmal atrial fibrillation
  • Individualized dosing to improve the efficacy and safety of long-term intravenous lidocaine infusion for patients undergoing thoracic surgery due to primary and secondary lung cancer – development of a pharmacokinetic population model for lidocaine and the metabolite MEGX
  • Effect of cysteine-lowering drugs on energy metabolism in humans
  • Therapeutic effects of BNP in Uncontrolled hypertensive patients 1

Contact information:
Hassan Z. Khiabani 
Department of Pharmacology, Oslo University Hospital, Rikshospitalet, PO Box 4956 Nydalen, NO-0424 Oslo, Norway
Tel +47 905 43 878 E-mail: haskhi@ous-hf.no